Diazoxide is a potassium ATP-channel opener that suppresses insulin secretion from pancreatic beta cells, used for persistent hypoglycaemia due to hyperinsulinism such as congenital hyperinsulinism in neonates and for insulinoma. Simson Pharma's Diazoxide reference standard and impurities support QC for this rare but critical paediatric metabolic therapy.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Diazoxide Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.